Source: Annual Congress 2007 - Molecular pathogenesis: focus on COPD and asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Plagens, J. Prakash Muyal, A. O. Yildirim, H. Fehrenbach, C. Vogelmeier, C. Seifart (Marburg, Germany). Surfactant proteins in elastase-induced emphysema – change after ATRA treatment?. Eur Respir J 2007; 30: Suppl. 51, 511

Member's Comments

No comment yet.

Related content which might interest you: Expression of MMPs in ATRA treated rats with elastase-induced emphysema Source: Eur Respir J 2007; 30: Suppl. 51, 141s Year: 2007 Dexamethasone inhibits surfactant degradation during bleomycin-induced lung injury in rats Source: Eur Respir J 2006; 28: Suppl. 50, 855s Year: 2006 Changes in pulmonary surfactant composition during bleomycin-induced lung injury Source: Eur Respir J 2006; 28: Suppl. 50, 397s Year: 2006 Translocation of TNF-α from the gut to the lung by VILI is reduced by exogenous surfactant therapy Source: Eur Respir J 2002; 20: Suppl. 38, 375s Year: 2002 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy Source: Eur Respir J 2014; 43: 1211-1212 Year: 2014 Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy Source: Eur Respir J 2013; 42: 350-361 Year: 2013 Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy Source: Eur Respir J 2014; 43: 1208-1211 Year: 2014 Surfactant therapy for post-bypass lung injury Source: Eur Respir J 2002; 20: Suppl. 38, 35s Year: 2002 Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Surfactant therapy for acute lung injury and other lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 210s Year: 2003 Surfactant protein D as a potential serum marker of pulmonary emphysema Source: Annual Congress 2011 - Smoking-related disorders and smoking prevention Year: 2011 IL-23 is essential to the development of elastase-induced pulmonary inflammation and emphysema Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Surfactant pretreatment preserves lung function in ischemia-reperfusion-injury of the lung Source: Eur Respir J 2005; 26: Suppl. 49, 221s Year: 2005 Surfactant therapy for ALI. Dose-effect relationship Source: Eur Respir J 2002; 20: Suppl. 38, 375s Year: 2002 Effect of simvastatin on bleomycin induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Angiotensin-(1-7) therapy attenuates pulmonary emphysema and sickness behavior induced by elastase in a murine model Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling Year: 2019 The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009